The treatment consists of a Bluetooth headset that patients can connect to an app on their smartphones. It could mark a ...

Researchers reveal that TMS repairs depression by regrowing dendritic spines on specific IT neurons in the prefrontal cortex.

ALTO-207 is a fixed-dose combination of pramipexole, a dopamine D3/D2 agonist with antidepressant activity demonstrated across multiple prior studies, and ondansetron, a 5-HT3 antagonist anti-emetic.

Researchers discover a paradox: high cognitive performance predicts depressive relapse, contradicting traditional expectations.

A study of 1,800 UK participants revealed that poorer cognitive performance did not predict depression relapse in previously ...

On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...

Young women with depression are more likely to have lower levels of taurine in their hippocampus than healthy controls. The corresponding study was published in Biological Psychiatry. Between 2013 and ...

Flow Neuroscience, a small Swedish company treating depression with brain-stimulating headsets, released early data on Monday showing that its device relieved depressive symptoms in clinical trials.

A new study found that depression may increase the risk of menstrual pain through factors like sleep disturbances. The findings suggest that treating sleep and mental health issues may help relieve ...

Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, ...

Alto Neuroscience is focused on developing precision medicine for mental health. On Tuesday, the company announced some promising signs for its treatment ALTO-100. The drug is geared toward treating a ...